Evidence map›Paper›PMID 41776549›Full record

ReviewBreast cancer research : BCR2026

Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer.

Yan Li, Wen Wang, Yan Liang, Houyun Lai, Kun Mi, Purong Zhang, Jianhui Zhang, Yixin Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yan LiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, China.
Wen WangSuining Central Hospital, Suining, 629000, Sichuan, China.
Yan LiangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, China.
Houyun LaiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, China.
Kun MiAffiliated Tumor Hospital of University of Electronic Science and Technology of China, Sichuan Cancer Hospital & Institute, Sichuan Cancer Prevention and Treatment Center, Chengdu, 610041, Sichuan, China.
Purong ZhangAffiliated Tumor Hospital of University of Electronic Science and Technology of China, Sichuan Cancer Hospital & Institute, Sichuan Cancer Prevention and Treatment Center, Chengdu, 610041, Sichuan, China.
Jianhui ZhangAffiliated Tumor Hospital of University of Electronic Science and Technology of China, Sichuan Cancer Hospital & Institute, Sichuan Cancer Prevention and Treatment Center, Chengdu, 610041, Sichuan, China.
Yixin WangAffiliated Tumor Hospital of University of Electronic Science and Technology of China, Sichuan Cancer Hospital & Institute, Sichuan Cancer Prevention and Treatment Center, Chengdu, 610041, Sichuan, China. wyxlxn5@163.com.

Funding

National Natural Science Foundation of China ZX2019001
6 · The paper itself

Abstract

HER2-positive breast cancer is characterized by aggressive tumor biology and intrinsic resistance to conventional therapies, underscoring the need for novel targeted treatment approaches. Pyrotinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), covalently binds to the intracellular kinase domains of HER1 (EGFR), HER2, and HER4, thereby inhibiting downstream signaling pathways and inducing tumor cell apoptosis. Clinical investigations have consistently demonstrated the substantial therapeutic efficacy of pyrotinib in both early-stage and advanced HER2-positive breast cancer. Moreover, its ability to traverse the blood-brain barrier confers potential therapeutic advantages in patients with brain metastases. This comprehensive review provides a systematic overview of the pharmacological profile and mechanism of action of pyrotinib, with emphasis on recent clinical trials assessing pyrotinib-based regimens in HER2-positive breast cancer.

Indexed as

AcrylamidesAminoquinolinesAntineoplastic AgentsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsAnimalsFemaleHumansSignal TransductionAcrylamidesAminoquinolinesAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorspyrotinibHER2-positive breast cancerPyrotinibTargeted drugTyrosine-kinase inhibitor (TKI)

Identifiers

PMID41776549
PMCPMC13169558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.